ivermectin - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

PCR-negative conversion 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
PCR-negative conversion (7-day) 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-

safety endpoints 00

adverse events 1.00 [0.20, 5.07]< 10%1 study (1/-)50.0 %lownot evaluable highnon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.